266 related articles for article (PubMed ID: 21854313)
1. Outlining novel cellular adjuvant products for therapeutic vaccines against cancer.
Tefit JN; Serra V
Expert Rev Vaccines; 2011 Aug; 10(8):1207-20. PubMed ID: 21854313
[TBL] [Abstract][Full Text] [Related]
2. Saponins from the Spanish saffron Crocus sativus are efficient adjuvants for protein-based vaccines.
Castro-Díaz N; Salaun B; Perret R; Sierro S; Romero JF; Fernández JA; Rubio-Moraga A; Romero P
Vaccine; 2012 Jan; 30(2):388-97. PubMed ID: 22079266
[TBL] [Abstract][Full Text] [Related]
3. IRX-2 increases the T cell-specific immune response to protein/peptide vaccines.
Naylor PH; Hernandez KE; Nixon AE; Brandwein HJ; Haas GP; Wang CY; Hadden JW
Vaccine; 2010 Oct; 28(43):7054-62. PubMed ID: 20708999
[TBL] [Abstract][Full Text] [Related]
4. Cancer vaccines: an update.
Hipp JD; Hipp JA; Lyday BW; Minev BR
In Vivo; 2000; 14(5):571-85. PubMed ID: 11125541
[TBL] [Abstract][Full Text] [Related]
5. Adjuvants for cancer vaccines.
Dubensky TW; Reed SG
Semin Immunol; 2010 Jun; 22(3):155-61. PubMed ID: 20488726
[TBL] [Abstract][Full Text] [Related]
6. Whole tumor cell vaccine with irradiated S180 cells as adjuvant.
Li J; King AV; Stickel SL; Burgin KE; Zhang X; Wagner TE; Wei Y
Vaccine; 2009 Jan; 27(4):558-64. PubMed ID: 19027812
[TBL] [Abstract][Full Text] [Related]
7. Genetically modified tumour vaccines--where we are today.
Nawrocki S; Mackiewicz A
Cancer Treat Rev; 1999 Feb; 25(1):29-46. PubMed ID: 10212588
[TBL] [Abstract][Full Text] [Related]
8. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity.
Speiser DE; Romero P
Semin Immunol; 2010 Jun; 22(3):144-54. PubMed ID: 20413326
[TBL] [Abstract][Full Text] [Related]
9. Toll-like receptor ligands energize peptide vaccines through multiple paths.
Celis E
Cancer Res; 2007 Sep; 67(17):7945-7. PubMed ID: 17804699
[TBL] [Abstract][Full Text] [Related]
10. Patented cancer vaccines: the promising leads.
Aurisicchio L; Ciliberto G
Expert Opin Ther Pat; 2010 May; 20(5):647-60. PubMed ID: 20345331
[TBL] [Abstract][Full Text] [Related]
11. Current adjuvants and new perspectives in vaccine formulation.
Montomoli E; Piccirella S; Khadang B; Mennitto E; Camerini R; De Rosa A
Expert Rev Vaccines; 2011 Jul; 10(7):1053-61. PubMed ID: 21806399
[TBL] [Abstract][Full Text] [Related]
12. Cancer vaccine adjuvants--recent clinical progress and future perspectives.
Banday AH; Jeelani S; Hruby VJ
Immunopharmacol Immunotoxicol; 2015 Feb; 37(1):1-11. PubMed ID: 25318595
[TBL] [Abstract][Full Text] [Related]
13. Immunity to melanoma antigens: from self-tolerance to immunotherapy.
Slingluff CL; Chianese-Bullock KA; Bullock TN; Grosh WW; Mullins DW; Nichols L; Olson W; Petroni G; Smolkin M; Engelhard VH
Adv Immunol; 2006; 90():243-95. PubMed ID: 16730266
[TBL] [Abstract][Full Text] [Related]
14. Melacine: an allogeneic melanoma tumor cell lysate vaccine.
Sosman JA; Sondak VK
Expert Rev Vaccines; 2003 Jun; 2(3):353-68. PubMed ID: 12903801
[TBL] [Abstract][Full Text] [Related]
15. Bacterial ghosts as adjuvant particles.
Riedmann EM; Kyd JM; Cripps AW; Lubitz W
Expert Rev Vaccines; 2007 Apr; 6(2):241-53. PubMed ID: 17408373
[TBL] [Abstract][Full Text] [Related]
16. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW
Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624
[TBL] [Abstract][Full Text] [Related]
17. T-cell epitope peptide vaccines.
Elsawa SF; Rodeberg DA; Celis E
Expert Rev Vaccines; 2004 Oct; 3(5):563-75. PubMed ID: 15485336
[TBL] [Abstract][Full Text] [Related]
18. Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults.
Vandepapelière P; Rehermann B; Koutsoukos M; Moris P; Garçon N; Wettendorff M; Leroux-Roels G
Vaccine; 2005 Apr; 23(20):2591-601. PubMed ID: 15780441
[TBL] [Abstract][Full Text] [Related]
19. Cancer vaccines: challenges and outlook in the field.
Paul S; Acres B; Limacher JM; Bonnefoy JY
IDrugs; 2007 May; 10(5):324-8. PubMed ID: 17487784
[TBL] [Abstract][Full Text] [Related]
20. Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience.
Mellstedt H; Vansteenkiste J; Thatcher N
Lung Cancer; 2011 Jul; 73(1):11-7. PubMed ID: 21474197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
